Organisational structure
During the reporting period, an organisational restructure was undertaken to respond to the evolving needs and priorities of the organisation. Most significantly, a Chief Operating Officer was appointed, with responsibility for safety and other responsibilities as outlined below, and a Nuclear Precinct established at the Lucas Heights campus. The Nuclear Precinct, under the leadership of Ms Pamela Naidoo-Ameglio, consolidates the operational functions of ANSTO Nuclear Medicine Pty Limited, Health Products, Reactor Operations and Waste Management.
Subsidiaries and companies
ANSTO has the following subsidiaries and company (where ANSTO possesses a material interest)
ANSTO subsidiaries | Jurisdiction of operation | Information/Status |
PETTECH Solutions Pty Ltd | NSW | PETTECH Solutions Pty Ltd is a small nuclear medicine diagnostic company and wholly owned ANSTO subsidiary. Its business operations were sold to Cyclotek NSW under a collaborative venture which will strengthen the PET imaging market and increase the research and development capability for new nuclear medicine diagnostics in New South Wales. |
ANSTO Nuclear Medicine Pty Ltd | NSW | ANSTO Nuclear Medicine Pty Ltd is the operating producer of one of the world’s most important nuclear medicines, Mo-99. The subsidiary will also participate and invest in nuclear medicine and related activities, including applied research and development aligned and complementary to its core facilities and competencies. |
ANSTO Inc. | Delaware, USA | Inactive |
ANSTO companies | ||
Applied Molecular Therapies Pty Ltd | Vic | Contract development and manufacturer of radiopharmaceutical products |
Visit
https://www.transparency.gov.au/annual-reports/australian-nuclear-science-and-technology-organisation/reporting-year/2019-20-25